Cargando…

Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy

PURPOSE: Proton therapy is an emerging therapy for several malignancies owing to its favorable therapeutic ratio. There are very limited data on the use of proton therapy in the management of thyroid carcinoma. Our objective was to review the safety, feasibility, and outcomes of proton therapy for p...

Descripción completa

Detalles Bibliográficos
Autores principales: Youssef, Irini, Yoon, Jennifer, Mohamed, Nader, Zakeri, Kaveh, Press, Robert H., Yu, Yao, Kang, Jung Julie, Wong, Richard J., Tuttle, R. Michael, Shaha, Ashok, Sherman, Eric, Lee, Nancy Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Particle Therapy Co-operative Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9415751/
https://www.ncbi.nlm.nih.gov/pubmed/36060412
http://dx.doi.org/10.14338/IJPT-22-00005.1
_version_ 1784776308972060672
author Youssef, Irini
Yoon, Jennifer
Mohamed, Nader
Zakeri, Kaveh
Press, Robert H.
Yu, Yao
Kang, Jung Julie
Wong, Richard J.
Tuttle, R. Michael
Shaha, Ashok
Sherman, Eric
Lee, Nancy Y.
author_facet Youssef, Irini
Yoon, Jennifer
Mohamed, Nader
Zakeri, Kaveh
Press, Robert H.
Yu, Yao
Kang, Jung Julie
Wong, Richard J.
Tuttle, R. Michael
Shaha, Ashok
Sherman, Eric
Lee, Nancy Y.
author_sort Youssef, Irini
collection PubMed
description PURPOSE: Proton therapy is an emerging therapy for several malignancies owing to its favorable therapeutic ratio. There are very limited data on the use of proton therapy in the management of thyroid carcinoma. Our objective was to review the safety, feasibility, and outcomes of proton therapy for patients with thyroid cancer treated to the head and neck. METHODS: From our institution's proton database from 2012 to 2021, we identified 22 patients with thyroid cancer treated with proton beam therapy. We evaluated outcomes and toxicities. RESULTS: Median follow-up was 26 months. Of the 22 patients, 50% were female. The mean age was 65 years. Three patients had anaplastic cancer; 13, papillary carcinoma; 2, follicular carcinoma; and 2, poorly differentiated carcinoma. Forty-six percent had T4 disease. Primary targets were the central neck compartment, level VI, and upper mediastinum. Radiation dose was 60 GyRBE adjuvantly, and 70 GyRBE for gross disease (range, 6000-7600 GyRBE). Eight patients underwent upfront adjuvant radiation, and 3 received definitive radiation for unresectable disease upfront. Eleven patients received either salvage or palliative radiation. Fifty-nine percent of patients had extrathyroidal extension, and 64% of patients had gross disease in the neck before treatment. Fifty percent of patients had metastatic disease before treatment. Sixteen patients received concurrent chemotherapy, 63% of these patients received doxorubicin. For all patients, 1-year local regional recurrence (LRR) was 0%, and overall survival (OS) was 90%. Acute grade 3+ toxicities occurred in 27% of patients, the most frequent being dermatitis (27%). Three patients required a percutaneous endoscopic gastrostomy tube after radiation therapy (RT), 2 owing to progression. There were no grade 4+ toxicities. CONCLUSIONS: Proton therapy for thyroid cancer appears feasible and effective with minimal toxicities. Prospective studies comparing proton therapy with intensity-modulated RT, to evaluate the clinical efficacy of using proton therapy to reduce toxicities in patients undergoing radiation for thyroid cancer, are warranted.
format Online
Article
Text
id pubmed-9415751
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Particle Therapy Co-operative Group
record_format MEDLINE/PubMed
spelling pubmed-94157512022-09-02 Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy Youssef, Irini Yoon, Jennifer Mohamed, Nader Zakeri, Kaveh Press, Robert H. Yu, Yao Kang, Jung Julie Wong, Richard J. Tuttle, R. Michael Shaha, Ashok Sherman, Eric Lee, Nancy Y. Int J Part Ther Original Articles PURPOSE: Proton therapy is an emerging therapy for several malignancies owing to its favorable therapeutic ratio. There are very limited data on the use of proton therapy in the management of thyroid carcinoma. Our objective was to review the safety, feasibility, and outcomes of proton therapy for patients with thyroid cancer treated to the head and neck. METHODS: From our institution's proton database from 2012 to 2021, we identified 22 patients with thyroid cancer treated with proton beam therapy. We evaluated outcomes and toxicities. RESULTS: Median follow-up was 26 months. Of the 22 patients, 50% were female. The mean age was 65 years. Three patients had anaplastic cancer; 13, papillary carcinoma; 2, follicular carcinoma; and 2, poorly differentiated carcinoma. Forty-six percent had T4 disease. Primary targets were the central neck compartment, level VI, and upper mediastinum. Radiation dose was 60 GyRBE adjuvantly, and 70 GyRBE for gross disease (range, 6000-7600 GyRBE). Eight patients underwent upfront adjuvant radiation, and 3 received definitive radiation for unresectable disease upfront. Eleven patients received either salvage or palliative radiation. Fifty-nine percent of patients had extrathyroidal extension, and 64% of patients had gross disease in the neck before treatment. Fifty percent of patients had metastatic disease before treatment. Sixteen patients received concurrent chemotherapy, 63% of these patients received doxorubicin. For all patients, 1-year local regional recurrence (LRR) was 0%, and overall survival (OS) was 90%. Acute grade 3+ toxicities occurred in 27% of patients, the most frequent being dermatitis (27%). Three patients required a percutaneous endoscopic gastrostomy tube after radiation therapy (RT), 2 owing to progression. There were no grade 4+ toxicities. CONCLUSIONS: Proton therapy for thyroid cancer appears feasible and effective with minimal toxicities. Prospective studies comparing proton therapy with intensity-modulated RT, to evaluate the clinical efficacy of using proton therapy to reduce toxicities in patients undergoing radiation for thyroid cancer, are warranted. The Particle Therapy Co-operative Group 2022-07-15 /pmc/articles/PMC9415751/ /pubmed/36060412 http://dx.doi.org/10.14338/IJPT-22-00005.1 Text en ©Copyright 2022 The Author(s) https://creativecommons.org/licenses/by/3.0/Distributed under Creative Commons CC-BY. Open Access (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ).
spellingShingle Original Articles
Youssef, Irini
Yoon, Jennifer
Mohamed, Nader
Zakeri, Kaveh
Press, Robert H.
Yu, Yao
Kang, Jung Julie
Wong, Richard J.
Tuttle, R. Michael
Shaha, Ashok
Sherman, Eric
Lee, Nancy Y.
Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy
title Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy
title_full Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy
title_fullStr Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy
title_full_unstemmed Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy
title_short Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy
title_sort outcomes and toxicities of nonmedullary thyroid tumors treated with proton beam radiation therapy
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9415751/
https://www.ncbi.nlm.nih.gov/pubmed/36060412
http://dx.doi.org/10.14338/IJPT-22-00005.1
work_keys_str_mv AT youssefirini outcomesandtoxicitiesofnonmedullarythyroidtumorstreatedwithprotonbeamradiationtherapy
AT yoonjennifer outcomesandtoxicitiesofnonmedullarythyroidtumorstreatedwithprotonbeamradiationtherapy
AT mohamednader outcomesandtoxicitiesofnonmedullarythyroidtumorstreatedwithprotonbeamradiationtherapy
AT zakerikaveh outcomesandtoxicitiesofnonmedullarythyroidtumorstreatedwithprotonbeamradiationtherapy
AT pressroberth outcomesandtoxicitiesofnonmedullarythyroidtumorstreatedwithprotonbeamradiationtherapy
AT yuyao outcomesandtoxicitiesofnonmedullarythyroidtumorstreatedwithprotonbeamradiationtherapy
AT kangjungjulie outcomesandtoxicitiesofnonmedullarythyroidtumorstreatedwithprotonbeamradiationtherapy
AT wongrichardj outcomesandtoxicitiesofnonmedullarythyroidtumorstreatedwithprotonbeamradiationtherapy
AT tuttlermichael outcomesandtoxicitiesofnonmedullarythyroidtumorstreatedwithprotonbeamradiationtherapy
AT shahaashok outcomesandtoxicitiesofnonmedullarythyroidtumorstreatedwithprotonbeamradiationtherapy
AT shermaneric outcomesandtoxicitiesofnonmedullarythyroidtumorstreatedwithprotonbeamradiationtherapy
AT leenancyy outcomesandtoxicitiesofnonmedullarythyroidtumorstreatedwithprotonbeamradiationtherapy